VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ use of basal-bolus insulin                         │ use of basal-bolus insulin                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ onset of diabetes after age 30                     │ onset of diabetes after age 30                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI less than 35                                   │ BMI less than 35                                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ eGFR at least 60 ml/mn                             │ eGFR at least 60 ml/mn                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hb A1c 7.0-10.0%                                   │ Hb A1c 7.0-10.0%                                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ willingness to perform home glucose monitoring     │ willingness to perform home glucose monitoring     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ willingness to transmit glucose and medication     │ willingness to transmit glucose and medication     │     100 │
│ information weekly                                 │ information weekly                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Type 1 diabetes                                    │ Type 1 diabetes                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known peripheral artery disease                    │ Known peripheral artery disease                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver enzymes equal or more than 1.5 times the     │ Liver enzymes equal or more than 1.5 times the     │     100 │
│ upper limit of normal                              │ upper limit of normal                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic heart failure NYHA class III or IV         │ Chronic heart failure NYHA class III or IV         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current haemodialysis or peritoneal dialysis       │ Current haemodialysis or peritoneal dialysis       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ End stage liver disease, defined as acute or       │ End stage liver disease, defined as acute or       │     100 │
│ chronic liver disease and recent history of one of │ chronic liver disease and recent history of one of │         │
│ the following: ascites, encephalopathy, variceal   │ the following: ascites, encephalopathy, variceal   │         │
│ bleeding, bilirubin equal or greater than 2.0      │ bleeding, bilirubin equal or greater than 2.0      │         │
│ mg/dL, albumin equal or less than 3.5 g/ dL,       │ mg/dL, albumin equal or less than 3.5 g/ dL,       │         │
│ prothrombin time greater or equal to 4 seconds,    │ prothrombin time greater or equal to 4 seconds,    │         │
│ INR greater than or equal to 1.7 or prior liver    │ INR greater than or equal to 1.7 or prior liver    │         │
│ transplant                                         │ transplant                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known or suspected hypersensitivity to trial       │ Known or suspected hypersensitivity to trial       │     100 │
│ products or related products                       │ products or related products                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female of child-bearing potential who is pregnant, │ Female of child-bearing potential who is pregnant, │     100 │
│ breast-feeding or intends to become pregnant or is │ breast-feeding or intends to become pregnant or is │         │
│ not using adequate contraceptive methods as        │ not using adequate contraceptive methods as        │         │
│ required by law or local practice                  │ required by law or local practice                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Expected simultaneous participation in any other   │ Expected simultaneous participation in any other   │     100 │
│ clinical trial of an investigational medicinal     │ clinical trial of an investigational medicinal     │         │
│ product                                            │ product                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Receipt of any investigational medicinal product   │ Receipt of any investigational medicinal product   │     100 │
│ within 30 days before randomization                │ within 30 days before randomization                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current or past (within the last 5 years)          │ Current or past (within the last 5 years)          │     100 │
│ malignant neoplasms (except basal cell and         │ malignant neoplasms (except basal cell and         │         │
│ squamous cell skin carcinoma)                      │ squamous cell skin carcinoma)                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition that in the investigator's opinion   │ Any condition that in the investigator's opinion   │     100 │
│ would make the subject unable to adhere to the     │ would make the subject unable to adhere to the     │         │
│ trial visit schedule and procedures                │ trial visit schedule and procedures                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known history of non-compliance to treatment       │ Known history of non-compliance to treatment       │     100 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                  │   Score │
╞═══════════════════════════════════╪════════════════════════════════╪═════════╡
│ Must have minimum age of 30 Years │ onset of diabetes after age 30 │      41 │
├───────────────────────────────────┼────────────────────────────────┼─────────┤
│ Must have maximum age of 70 Years │ onset of diabetes after age 30 │      41 │
╘═══════════════════════════════════╧════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 94.63636363636364
OverAll Ratio: 96.31818181818181
